Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 40Triple Negative Breast Neoplasms 34Carcinoma, Non-Small-Cell Lung 11Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 5Brain Neoplasms 5Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Glioblastoma 3Uterine Cervical Neoplasms 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Uterine Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Localized Muscle Invasive Bladder Urothelial Carcinoma × sacituzumab govitecan × Clear all
NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Case Comprehensive Cancer Center

Phase 1 Recruiting
20 enrolled
Genitourinary

Localized Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡